We are live on ! Find out more
EVGN icon

Evogene

15 hedge funds and large institutions have $52M invested in Evogene in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

14% more capital inflows, than outflows

Capital inflows: $4.47M | Capital outflows: $3.91M

2.51% more ownership

Funds ownership: 19.8% → 22.31% (+2.5%)

0% more funds holding

Funds holding: 15 → 15 (0)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

EVGN Hedge Fund Activity: Q4 2014 in Review

15 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2014, worth a combined $52M — down 20% from $65.1M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EVGN and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.

The largest buyer was Goldman Sachs, adding an estimated $2.81M. The largest seller was Credit Suisse, exiting entirely with an estimated $1.32M sold.

  • 15 institutional investors held Evogene (EVGN) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $52M of Evogene stock for Q4 2014, down 20% quarter-over-quarter.
  • 1 fund opened new Evogene positions in Q4 2014 and 2 closed out, a net change of -1 holder.
  • The largest Evogene buyer in Q4 2014 was Goldman Sachs, an estimated $2.81M added.
  • The largest Evogene seller in Q4 2014 was Credit Suisse, an estimated $1.32M sold.

Based on aggregated 13F filings for Q4 2014.